SCHEMBL6284097

SCHEMBL6284097

Cc1cccc2c(CC(=O)O)c[nH]c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.58
MAPT P10636 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
BRPF1 P55201 1/20 0.55
KDM4E B2RXH2 3/20 0.55
MEN1 O00255 2/20 0.55
GAA P10253 2/20 0.55
KMT2A Q03164 2/20 0.55
SOS2 Q07890 1/20 0.55
NR4A2 P43354 1/20 0.51
TRIM24 O15164 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
PCSK9 Q8NBP7 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 2/20 0.46
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
TSHR P16473 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3611008 0.86 HTR2A (0.60) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL5694492 0.85 TDP1 (0.53) MAPTSMN1; SMN2NPSR1KDM4EMEN1
SCHEMBL24814480 0.84 SOS2 (0.60) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL10678420 0.84 HTR2A (0.63) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL6131640 0.84 ALDH1A1 (0.57) MAPTSMN1; SMN2NPSR1KDM4EMEN1
SCHEMBL17102847 0.83 ALDH1A1 (0.59) MAPTSMN1; SMN2NPSR1KDM4EMEN1
SCHEMBL5058671 0.82 ALDH1A1 (0.46) MAPTSMN1; SMN2NPSR1KDM4EMEN1
SCHEMBL21808837 0.82 PKM (0.66) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL23360640 0.81 HTR2A (0.55) HTR2AMAPTSMN1; SMN2NPSR1BRPF1
SCHEMBL8297888 0.81 HTR2A (0.67) HTR2AMAPTSMN1; SMN2NPSR1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119332255-A Electrochemical synthesis method of arundone derivatives 云南师范大学 2025-01-21 CN claimed
CN-117946367-A Preparation method of water-based polyurethane leather coating containing natural antibacterial factors 四川大学 2024-04-30 CN claimed
EP-3636642-B1 INDOLEACETIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF COUGH INST CHINESE MATERIA MEDICA CHINA ACADEMY OF CMS (CN) 2025-12-24 EP disclosed
CN-119332255-A Electrochemical synthesis method of arundone derivatives 云南师范大学 2025-01-21 CN disclosed
CN-119307565-A Method for synthesizing L-7-methyl tryptophan by enzyme method 浙江普洛生物科技有限公司 2025-01-14 CN disclosed
CN-117946367-A Preparation method of water-based polyurethane leather coating containing natural antibacterial factors 四川大学 2024-04-30 CN disclosed
US-11008360-B2 Indoleacetic acid derivative and preparation method and pharmaceutical use thereof INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) 2021-05-18 US disclosed
US-11008360-B2 Indoleacetic acid derivative and preparation method and pharmaceutical use thereof INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) 2021-05-18 US disclosed
EP-3636642-A1 INDOLEACETIC ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF Institute Of Chinese Materia Medica China Academy of Sciences (CN) 2020-04-15 EP disclosed
EP-3636642-A1 INDOLEACETIC ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF Institute Of Chinese Materia Medica China Academy of Sciences (CN) 2020-04-15 EP disclosed
US-20200095271-A1 INDOLEACETIC ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) 2020-03-26 US disclosed
US-20200095271-A1 INDOLEACETIC ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) 2020-03-26 US disclosed
CN-103347874-B dimeric IAP inhibitors NOVARTIS AG (CH) 2014-10-29 CN disclosed
CN-103347874-A Dimeric iap inhibitors NOVARTIS AG 2013-10-09 CN disclosed
CN-102770425-A Indolyl-piperidinylbenzylamines as beta-tryptase inhibitors SANOFI SA 2012-11-07 CN disclosed
US-6887890-B2 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-05-03 US disclosed
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-28 US disclosed
EP-1291341-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200095271-A1 INDOLEACETIC ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF IDO1, IDO2, TPH1 HTR2A 18/4885MAPT 1307/4885SMN1; SMN2 4038/4885
US-11008360-B2 Indoleacetic acid derivative and preparation method and pharmaceutical use thereof IDO1, IDO2, TPH1 HTR2A 18/4885MAPT 1307/4885SMN1; SMN2 4038/4885
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities MPL, THPO, TEK HTR2A 799/4885MAPT 4866/4885SMN1; SMN2 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.